Clinical and pathophysiological consequences of on-demand treatment with PPI in endoscopy-negative reflux disease. Is rebound hypersecretion of acid a problem?

Objective: Rebound acid hypersecretion after withdrawal of proton pump inhibitor (PPI) may lead to symptom aggravation and difficulties in withdrawing anti-reflux medication. The aim was to investigate pathophysiological and clinical consequences of on-demand treatment with PPI in patients with endoscopy-negative reflux disease.

Material And Methods: Twenty-six patients with endoscopy-negative reflux disease were investigated for rebound effects of lansoprazole 15 mg, used on-demand, maximum 4 capsules daily during a 6-month period.

On-demand PPI requirements in patients with endoscopy-negative GERD.

Goals: To evaluate the need for on-demand treatment with proton pump inhibitor in patients with endoscopy-negative GERD.

Background: Studies indicate that on-demand therapy is suitable for patients without mucosal disease, but the need for PPI in a monotherapy situation is not known.

Study: Forty-one patients with heartburn and/or acid reflux of more than 3 months duration participated in the study.